Although a great interest in TREM2 as a therapeutic target for AD is emerging, it remains a challenging task, since TREM2 risk variants are found in less than 1% of the population, and it is still unknown whether potential TREM2 targeting could be effective in non-carrier AD patients [88]. The gene discussed is TREM2; the disease is Alzheimer disease.